Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
letter
. 2005 Sep;49(9):3980–3981. doi: 10.1128/AAC.49.9.3980-3981.2005

Impact of Initial Antimicrobial Therapy in Patients with Bloodstream Infections Caused by Stenotrophomonas maltophilia

Gokhan Metan 1,*, Omrum Uzun 1
PMCID: PMC1195400  PMID: 16127088

The impact of inappropriate initial antimicrobial therapy on the outcomes of patients with bloodstream infections caused by antibiotic-resistant gram-negative bacilli is not well defined. Recently, in an interesting study by Kang et al., inappropriate initial antimicrobial therapy was found to be associated with an adverse outcome, particularly in patients with a high-risk source of bacteremia caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., and Pseudomonas aeruginosa (1). In addition to the source of bacteremia, presentation with septic shock, P. aeruginosa infection, and an increasing acute physiology, age, and chronic health evaluation (APACHE II) score were poor prognostic factors in this study.

Stenotrophomonas maltophilia is an emerging nosocomial pathogen with a tendency to be resistant to several antibiotics commonly used to treat nosocomial infections. Although a recent study reported no significant difference in the outcomes of patients who received appropriate therapy and outcomes of patients who received inappropriate therapy (2), at least two case-controlled studies described inappropriate therapy as an independent risk factor for mortality (3, 4).

At our center (Hacettepe University School of Medicine Hospital, a 1,000-bed tertiary-care teaching hospital), we evaluated the factors that influenced the outcomes in patients with bacteremia caused by S. maltophilia. We retrospectively reviewed the reports of our clinical microbiology laboratory to identify the study patients during a six-year period from 1998 to 2004. Case patients were defined as those who were >16 years of age, had at least one blood culture positive for S. maltophilia, and had clinical signs of systemic infection. The mortality rate 30 days after the onset of bacteremia was used as the main outcome measure. Appropriate therapy was defined as one or more agents active against S. maltophilia, given adequate dose and route of administration, not later than 24 h after the blood culture was obtained. All statistical analyses were performed by using SPSS software (version 10.0; SPSS, Chicago, IL). Numerical data were reported (medians and interquartile ranges). To test for the differences between quantitative variables between appropriate and inappropriate therapies, independent-sample t tests were used for normally distributed variables. Differences between categorical variables were analyzed by the chi-square test with the continuity correction or the Fisher exact test where appropriate.

Fifty-six patients with S. maltophilia bacteremia were identified. A total of 41 patients were included in the analysis. Fifteen cases whose medical records contained missing data were excluded from the study. The overall 30-day mortality rate was 31.7%. The patients who died within 30 days after the onset of S. maltophilia bacteremia had a longer duration of hospitalization and a higher rate of intensive care unit stay (at the time of initial bacteremia), as well as an increased need for mechanical ventilation and presentation with septic shock (Table 1). Twelve (29.2%) patients had received inappropriate therapy. Eight (66.7%) patients who were treated inappropriately died, compared to 5 (17.2%) of 29 who died though they received an appropriate antibiotic(s). Six of 8 (75.0%) patients who died were on carbapenems when S. maltophilia bacteremia developed.

TABLE 1.

Demographic characteristics of the patients with bloodstream infection caused by S. maltophilia

Demographic characteristicc Value for indicated group
Total (n = 41) Patients who died (n = 13)a Surviving patients (n = 28) Pb
Age (mean yrs) 50.90 52.08 50.36 NS
Sex (no. of males/no. of females) 17/24 7/6 10/18 NS
No. of patients with indicated underlying illness or transplant
    Hematological malignancy 15 5 10 NS
    Solid tumor 4 2 2 NS
    Solid organ transplant 1 0 1 NS
    Chronic renal failure 5 2 3 NS
    Chronic liver disease 1 0 1 NS
    Diabetes mellitus 3 2 1 NS
Duration of hospitalization before onset of bacteremia (median days) 24 45 21 0.049
    Major surgery 8 5 3 0.037
    Central venous catheter 37 12 25 NS
    Mechanical ventilation 11 8 3 0.001
    Previous antimicrobial therapy 39 12 27 NS
    ICU stay at time of initial bacteremia 12 7 5 0.018
    Neutropenia 13 4 9 NS
No. of patients with:
    Therapy
        Appropriate 29 5 24 0.002
        Inappropriate 12 8 4 <0.001
    Septic shock 7 7 0 <0.001
    Indicated primary source     of the bacteremia
        Pneumonia 5 3 2 NS
        Central venous         catheter 9 2 7 NS
        Postsurgical-wound         infection 1 0 1 NS
        Unknown source of         bacteremia 26 8 18 NS
a

Thirty-day mortality.

b

NS, not significant.

c

ICU, intensive care unit. Neutropenia was defined as an absolute neutrophil count below 500 cells/mm3. Septic shock was defined as sepsis associated with evidence of organ hypoperfusion and a systolic blood pressure 90 or 30 mm Hg less than the baseline or a requirement for the use of a vasopressor to maintain blood pressure.

In this limited study, we have shown a higher mortality rate for the bacteremic patients who did not receive appropriate therapy against S. maltophilia. We believe this issue should be further evaluated by case-controlled studies with a higher number of patients who had similar comorbid factors. In addition, the practicing physician should consider S. maltophilia as the causative organism in a patient who deteriorates under carbapenem therapy.

Acknowledgments

We thank Mine Durusu for statistical analysis.

REFERENCES

  • 1.Kang, C.-I., S.-H. Kim, W. B. Park, et al. 2005. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob. Agents Chemother. 49:760-766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lai, C. H., C. Y. Chi, H. P. Chen, et al. 2004. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J. Microbiol. Immunol. Infect. 37:350-358. [PubMed] [Google Scholar]
  • 3.Micozzi, A., M. Venditti, M. Monaco, A. Friedrich, F. Taglietti, S. Santilli, and P. Martino. 2000. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin. Infect. Dis. 31:705-711. [DOI] [PubMed] [Google Scholar]
  • 4.Senol, E., J. DesJardin, P. C. Stark, L. Barefoot, and D. R. Snydman. 2002. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin. Infect. Dis. 34:1653-1656. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES